ABSTRACT
ObjectiveTo investigate the protective effect of hepatocyte growth-promoting factor (PHGF) against liver ischemia-reperfusion injury in rats and its mechanism of its action. MethodsA total of 80 healthy male Sprague-Dawley rats were randomly divided into experimental group (PHGF group) and control group (NS group), with 40 rats in each group. A rat model of liver ischemia-reperfusion injury was established by 70% liver ischemia caused by the occlusion of blood flow in the middle and left lobes of the liver, with an ischemia time of 21 minutes. The rats in the PHGF group were given intraperitoneal injection of PHGF for intervention before surgery, and those in the NS group were given an equal volume of normal saline. Serum and liver tissue samples were collected before surgery and on days 1, 3, 5, and 7 after surgery, and the levels of alanine aminotransferase (ALT), aspartate aminotransferase (AST), and total bilirubin (TBil) were measured; HE staining was used to observe pathological changes; real-time PCR was used to measure the mRNA expression of mitochondrial transcription factor A (TFAM) in the liver. The independent samples t-test was used for comparison of continuous data between two groups. ResultsHE staining showed that compared with the NS group, the PHGF group had significantly lower degrees of hepatocyte swelling, inflammatory cell infiltration, and hepatocyte necrosis under a light microscope. Liver biochemistry showed that on days 1, 3, 5, and 7 after surgery, the PHGF group had significantly lower serum levels of ALT, AST, and TBil than the NS group (t=11.879, 16.019, 22168, 10.235, 9.041, 12.936, 18.759, 8.142, 10.108, 11.014, 13.245, and 9.968, all P＜0.001). Real-time PCR showed that on days 1, 3, and 5 after surgery, the PHGF group had a significantly higher mRNA level of TFAM in the liver than the NS group (t=7998, 14.764, and 13.861, all P＜0.001). ConclusionPHGF preconditioning exerts a protective effect against liver ischemia-reperfusion injury in rats, possibly by upregulating the expression of TFAM to alleviate liver ischemia-reperfusion injury.
ABSTRACT
Objective: To observe the influence of hepatocyte growth-promoting factor (pHGF) on monocyte chemotatic protein-1-(MCP-1) and aristolochic acid I (AA I )-induced epithelial-to-mesenchymal transition (EMT) and apoptosis of human kidney epithelial cell line(HKC). Methods: The HKC cells were randomly divided into blank control group (control groups), epithelial-to-mesenchymal transition model group (model group), and pHGF inhibition group (pHGF groups) with pHGF at different concentrations (0. 15, 1. 5, 15, 150, and 1 500 ng/ml). The EMT model was established by exposing HKC cells to MCP-1 (0. 1 μg/ml)and AA I (10 μg/ml). Cells in the pHGF groups were the model cells treated with different concentrations of pHGF. Cells in the control group were cultured routinely. WST-8 method and flow cytometry were used to observe the proliferation and apoptosis of HKC cells, respectively. The mRNA expression of α-smooth muscle actin(α-SMA) was determined by reverse transcriptase-polymerase chain reaction (RT-PCR), and the expression of α-SMA, fibronectin (FN), and transforming growth factor-β1 (TGF-β1) in HKC cells were assessed by indirect enzyme immunohistochemistry. Results: The cell inhibitory rate, apoptotic rate, and expression of α-SMA mRNA were significantly increased in the model group and pHGF groups compared with those in the control group (P<0. 01), indicating the successful establishment of EMT model. Compared with the model group, pHGF at 150 ng/ml, but not at other concentrations, significantly decreased the inhibition rate of HKC cells(P<0. 01). The apoptotic rate of HKC cells in all the pHGF groups were significantly lower than that in the model group (P<0. 01), pHGF at 150 ng/ml also greatly decreased the expression of α-SMA mRNA, and significantly down-regulated the expression of α-SMA, TGF-β1, and FN protein. Conclusion: pHGF at 150 ng/ml can partly reverse MCP-1- and AA I -induced HKC cell growth inhibition, apoptosis, and EMT.
ABSTRACT
Objective To explore the effects of hepatocyte growth-promoting factor(pHGF) on renal function and cell apoptosis in kidney of rats with renal ischemia reperfusion injury(IRI).Methods Thirty-two male Sprague-Dawley rats were divided into 4 groups:sham-operated control group(groupⅠ),renal ischemia reperfusion control group(groupⅡ),one experimental group injecting pHGF(50 mg/kg,intraabdominal injection) before renal IRI(group Ⅲ),and another experimental group injecting pHGF(50 mg/kg,intraabdominal injection) after renal IRI(group Ⅳ).The animals with renal IRI exposed to 45 min bilateral renal pedicle clamping.All ischemia reperfusion rats in group Ⅰ and Ⅱ were intraabdomially injected equal volume of physiological saline(0.8 mL) at the time when the rats in experimental groups were administered 50 mg/kg pHGF.Twelve hours after IRI,samples for serum and the left renal tissue of each animal were taken.The serum sample was used to detect expression of serum creatinine(Scr),and the renal tissue sample for evaluation of apoptosis.Results Compared with the level of Scr in groupⅠ(22.775?6.508) ?mol/L,Scr was markedly higher in groupⅡ(120.850?22.237) ?mol/L(P0.05).Conclusions The laboratory investigation suggests that pHGF might be an effective pharmacological agent against renal IRI according to the findings of the evaluated parameters,and protective effect by pHGF against renal IRI might involved in the mechanisms decreasing tubular cells apoptosis.It is likely that pHGF is a potential therapentic agent in clinical renal IRI circumstances.
ABSTRACT
AIM: To observe the therapeutic effect of hepatocyte growth promoting factor (PHGF) combined with transmetil in treatment of chronic severe hepatitis (CSF). METHODS: 120 patients were divided randomly into two groups: the combined treatment group and the routine group. All the patients received ordinary therapy, and 62 patients, based on the therapy, received PHGF combined with transmetil in the combined treatment group. RESULTS: Compared with the routine treatment group, the levels of total serum bilirubin and prothrombin time were decreased significantly (P
ABSTRACT
OBJECTIVE:To study the therapeutic efficacy of compound glycyrrhizin tablets(SNMC)combined with hep?atocyts growth-promoting factor(PHGF)in the treatment of severe hepatitis.METHODS:126patients with severe hepatitis were randomly divided into the trial group and the control group.RESULTS:The effective rate was87.2%in the trial group and70.0%in the control group,which existed a significant difference(P